Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced ...

Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, ...

Rebranding efforts include a new logo, overall brand presence, and corporate design.